Healthy Participants Study Clinical Trial
Official title:
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, And Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Participants
This study will assess the safety, tolerability and pharmacokinetics (PK) of AZD0292 following intravenous (IV) administration of single ascending doses to healthy adult participants.
This is a First-time-in-human (FTiH) trial. Eligible participants will be randomized to receive AZD0292 or Placebo. Participants will receive pre-medication with an antihistamine prior to dosing with the study intervention. The study will comprise: 1. A Screening Period of maximum 28 days. 2. A Treatment Period 3. A Follow-up Period from Day 3 to Day 16 4. An extended Follow-up Period from Day 17 to Day 61 Participants will be involved in this study for a maximum duration of 13 weeks. ;